Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 3,528 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: biospecimen Collection Clear all

Conditions: Influenza, Human
Interventions: Blood sample, Nasal swab, Oropharyngeal swab, Stool sample, Symptom checklist; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Neuroblastoma
Interventions: beta-glucan, monoclonal antibody 3F8, immunohistochemistry staining method, laboratory biomarker analysis; Biological · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 0 Years to 120 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Educational Intervention, Electronic Health Record Review, Interview, Survey Administration; Procedure · Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cervical Cancer
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 25 Years to 70 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetic Retinopathy
Interventions: Blood draw; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: Pain, Postoperative
Interventions: CYP2D6-guided opioid therapy; Genetic
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Gainesville, Florida • Summerfield, Florida

Conditions: Solid Tumor Malignancies, Metastatic Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Bladder Cancer
Interventions: Expert Review, Blood or tissue samples collection., The Precision Oncology Navigation; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Ovary Cancer
Interventions: EC1456, 99mTc-Etarfolatide; Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Concord, North Carolina

Conditions: Bioequivalence
Interventions: Tacrolimus; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Epidermolysis Bullosa, Healthy, Genetic Skin Disease, Epidermolysis Bullosa Simplex, Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica
Interventions: Experimental Group; Procedure
Lead sponsor: Joyce Teng; Other
Eligibility: 0 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Type II Diabetes, Periodontal Disease
Interventions: Triclosan containing toothpaste, Non-triclosan containing toothpaste; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Choroid Plexus Neoplasm, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Ependymoma, Newly Diagnosed Childhood Ependymoma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified, Recurrent Childhood Visual Pathway Glioma
Interventions: Cytology Specimen Collection Procedure; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 18 Years
Enrollment: 1,258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 163
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 123 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Entinostat, Exemestane, Goserelin, Goserelin Acetate, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 652
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Carmichael, California + 460 more

Conditions: Breast Cancer
Interventions: questionaire, blood or saliva sample; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 54 Years · Female only
Enrollment: 1,699 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 4
States / cities: Stanford, California • Iowa City, Iowa • New York, New York + 1 more

Conditions: Allogeneic Hematopoietic Stem Cell Transplant Recipient, Donor, Malignant Neoplasm
Interventions: Biospecimen Collection-Blood, Biospecimen Collection-Stool; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: COVID-19
Interventions: Self-administered saliva-based viral testing; Diagnostic Test
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
Interventions: Bone Marrow Biopsy, Epoetin Alfa, Laboratory Biomarker Analysis, Lenalidomide; Procedure · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 507
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 345 more

Conditions: Sickle Cell Disease, Thalassemia, Beta, Thalassemia Alpha, Hemoglobinopathies
Interventions: GWAS; Genetic
Lead sponsor: Cyprus Institute of Neurology and Genetics; Other
Eligibility: 2 Years and older
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Oxygen Saturation
Interventions: INVSENSOR00045; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: Up to 1 Month
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Orange, California

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Blood collection, Tissue collection; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib; Procedure · Drug
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more

Conditions: Human Papillomavirus
Interventions: Alinity m HR HPV; Diagnostic Test
Lead sponsor: Abbott Molecular; Industry
Eligibility: 25 Years and older · Female only
Enrollment: 14,935 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 63
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more

Conditions: Human Immunodeficiency Virus, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, High-Grade Squamous Intraepithelial Lesions
Interventions: Biospecimen Collection, Questionnaires; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions: Biospecimen Collection, Laboratory Biomarker Analysis; Procedure · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

A Pilot Study of Influenza Viruses Isolated From Immunocompromised Children and Adolescents

Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma

A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors Post-treatment

Cervical Cancer Screening Project Part C

Biomarker of Diabetic Retinopathy

Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery

Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers

Computational Drug Repurposing for All EBS Cases

Periodontal Treatment Response in Type II Diabetic Patients

Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Study of Radiation Exposure and Bilateral Breast Cancer

Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant

COVID-19 Screening Program

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Study of the Role of Genetic Modifiers in Hemoglobinopathies

Convenience Sample Data Collection for INVSENSOR00045

Memory Phenotype and PD-1 Inhibition Response in Oral Cancer

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Alinity m HR HPV Specimen Collection Study From Women Undergoing Routine Cervical Cancer Screening

Anal High-risk HPV, HSIL, and Microbiome Among Hispanic Peoples Living With HIV (PLWH)

Collection of Blood Samples in Patients With Non-small Cell Lung Cancer